Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

triple agonist

Obesity Weekly News

Obesity Video Recap—February 3, 2026

This biweekly Obesity video recap highlights key developments across clinical…

Obesity Weekly News

Obesity Today—December 16, 2025

Explore this week’s obesity highlights, including new developments, pipeline…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Cardiovascular Today—March 19, 2026
Rare Diseases Today—March 19, 2026
Cell and Gene Therapy Today—March 19, 2026
Lucid Diligence Brief: Crossbow Therapeutics $77 million Series B for TCR-mimetics
Women’s Health Today—March 18, 2026

Tags

Acer Medical Alpha-1 antitrypsin deficiency AltaValve arrhythmias cancer care cancer vaccines clinical validation CMS competitive advantage Dual agonist therapy EGFR-mutated non-small cell lung cancer EMA ODD FDA endocrinology approvals HeartFlow Hematology market trends hepatitis D Huons IL-17 inhibitor inflammatory polyneuropathies ITM Isotope Technologies Munich ivc thrombectomy JUXTAPID mavacamten microglia. Minimally invasive surgery Natalizumab Nipocalimab OnabotulinumtoxinA Pain pertussis Pluristyx Quince Therapeutics RAM endpoints retatrutide rosacea Rubraca Sapien M3 Severe aplastic anemia Stem-cell diabetes therapy surgical robotics T-cell engager Tecvayli Venous thromboembolism YorLabs Zika vaccine

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Cardiovascular Today—March 19, 2026
Rare Diseases Today—March 19, 2026
Cell and Gene Therapy Today—March 19, 2026
Lucid Diligence Brief: Crossbow Therapeutics $77 million Series B for TCR-mimetics
Women’s Health Today—March 18, 2026

TAGS

Acer Medical Alpha-1 antitrypsin deficiency AltaValve arrhythmias cancer care cancer vaccines clinical validation CMS competitive advantage Dual agonist therapy EGFR-mutated non-small cell lung cancer EMA ODD FDA endocrinology approvals HeartFlow Hematology market trends hepatitis D Huons IL-17 inhibitor inflammatory polyneuropathies ITM Isotope Technologies Munich ivc thrombectomy JUXTAPID mavacamten microglia. Minimally invasive surgery Natalizumab Nipocalimab OnabotulinumtoxinA Pain pertussis Pluristyx Quince Therapeutics RAM endpoints retatrutide rosacea Rubraca Sapien M3 Severe aplastic anemia Stem-cell diabetes therapy surgical robotics T-cell engager Tecvayli Venous thromboembolism YorLabs Zika vaccine

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy